OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $67,793 | -86.9% | 21,590 | -78.4% | 0.01% | -90.2% |
Q2 2023 | $516,000 | -51.0% | 100,000 | -50.0% | 0.08% | -65.7% |
Q1 2023 | $1,054,000 | +87.5% | 200,000 | 0.0% | 0.24% | +75.7% |
Q4 2022 | $562,000 | -48.9% | 200,000 | -24.5% | 0.14% | -37.9% |
Q3 2022 | $1,099,000 | +647.6% | 265,000 | +793.9% | 0.22% | +1052.6% |
Q1 2022 | $147,000 | -23.0% | 29,644 | +7.6% | 0.02% | -32.1% |
Q4 2021 | $191,000 | -97.5% | 27,551 | -96.4% | 0.03% | -94.8% |
Q3 2021 | $7,707,000 | -51.5% | 770,751 | -31.2% | 0.54% | -57.8% |
Q2 2021 | $15,879,000 | +42.0% | 1,119,573 | +64.2% | 1.28% | +240.6% |
Q1 2021 | $11,186,000 | -45.8% | 681,673 | -31.6% | 0.38% | -58.6% |
Q4 2020 | $20,632,000 | +58.0% | 996,673 | -41.9% | 0.91% | -3.7% |
Q3 2020 | $13,061,000 | -23.7% | 1,716,293 | -16.5% | 0.94% | -30.7% |
Q2 2020 | $17,126,000 | +121.9% | 2,055,977 | +31.9% | 1.36% | +135.0% |
Q1 2020 | $7,717,000 | +176.0% | 1,558,936 | +120.3% | 0.58% | +28.0% |
Q4 2019 | $2,796,000 | – | 707,659 | – | 0.45% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |